Diagnostic tests make inroads in market; Stemina was past BPC finalist

January 30, 2012

When thalidomide came to market in the 1950s as a morning sickness treatment, no one imagined the many cases of birth defects that would result from use of the drug. More than 50 years later, a small Madison-based stem cell company is selling a research product that could have prevented what some have called one of the biggest medical tragedies of modern times. Read more here.

Comments are closed.